The objective of this study is to assess the pharmacokinetics (PK), safety, and tolerability of ABBV-903 or placebo in healthy adult Japanese and Han Chinese subjects.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Enrollment
24
Tablet; oral
Tablet; oral
Anaheim Clinical Trials LLC /ID# 257033
Anaheim, California, United States
Maximum observed plasma concentration (Cmax) of ABBV-903
Cmax of ABBV-903 will be assessed.
Time frame: Up to Day 4
Time to Cmax (Tmax) of ABBV-903
Tmax of ABBV-903 will be assessed.
Time frame: Up to Day 4
Apparent Terminal Phase Elimination Rate Constant (β) of ABBV-903
Apparent terminal phase elimination rate constant (β) of ABBV-903 will be assessed.
Time frame: Up to Day 4
Terminal Phase Elimination Half-life (t1/2) of ABBV-903
Terminal phase elimination half-life (t1/2) of ABBV-903 will be assessed.
Time frame: Up to Day 4
Area under the Plasma Concentration-time Curve (AUC) from Time 0 to the Time t (AUC0-t) of ABBV-903
AUC0-t of ABBV-903 will be assessed.
Time frame: Up to Day 4
AUC from Time 0 to Infinity (AUC0-inf) of ABBV-903
AUC0-inf of ABBV-903 will be assessed.
Time frame: Up to Day 4
Number of Participants with Adverse Events (AEs)
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.
Time frame: Baseline to Day 34
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.